CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
2.24
0.89%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Graphite Bio Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.26
Open* 2.23
1-Year Change* -35.36%
Day's Range* 2.21 - 2.25
52 wk Range 1.59-3.64
Average Volume (10 days) 203.93K
Average Volume (3 months) 2.69M
Market Cap 134.55M
P/E Ratio -100.00K
Shares Outstanding 58.00M
Revenue N/A
EPS -2.24
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 2.24 0.01 0.45% 2.23 2.25 2.17
Nov 30, 2023 2.26 0.09 4.15% 2.17 2.27 2.17
Nov 29, 2023 2.23 0.00 0.00% 2.23 2.29 2.17
Nov 28, 2023 2.23 -0.07 -3.04% 2.30 2.33 2.16
Nov 27, 2023 2.34 0.05 2.18% 2.29 2.37 2.29
Nov 24, 2023 2.29 0.01 0.44% 2.28 2.34 2.28
Nov 22, 2023 2.29 0.00 0.00% 2.29 2.33 2.23
Nov 21, 2023 2.31 0.01 0.43% 2.30 2.40 2.28
Nov 20, 2023 2.32 0.06 2.65% 2.26 2.36 2.26
Nov 17, 2023 2.30 0.06 2.68% 2.24 2.31 2.23
Nov 16, 2023 2.23 0.09 4.21% 2.14 2.27 2.14
Nov 15, 2023 2.24 0.10 4.67% 2.14 2.27 2.00
Nov 14, 2023 2.30 0.02 0.88% 2.28 2.34 2.26
Nov 13, 2023 2.28 0.01 0.44% 2.27 2.30 2.24
Nov 10, 2023 2.31 0.04 1.76% 2.27 2.32 2.25
Nov 9, 2023 2.32 0.02 0.87% 2.30 2.37 2.27
Nov 8, 2023 2.36 0.03 1.29% 2.33 2.41 2.30
Nov 7, 2023 2.38 0.06 2.59% 2.32 2.41 2.32
Nov 6, 2023 2.39 0.10 4.37% 2.29 2.42 2.21
Nov 3, 2023 2.27 -0.08 -3.40% 2.35 2.38 2.27

Graphite Bio, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 0 0 0 0
Total Operating Expense 105.639 60.443 13.5 0.029
Selling/General/Admin. Expenses, Total 32.852 22.511 4.377 0.029
Research & Development 72.787 37.932 9.123 0
Operating Income -105.639 -60.443 -13.5 -0.029
Interest Income (Expense), Net Non-Operating 0 -0.04 -0.08
Other, Net 4.587 -10.317 -54.833 0
Net Income Before Taxes -101.052 -70.76 -68.373 -0.109
Net Income After Taxes -101.052 -70.76 -68.373 -0.109
Net Income Before Extra. Items -101.052 -70.76 -68.373 -0.109
Net Income -101.052 -70.76 -68.373 -0.109
Income Available to Common Excl. Extra. Items -101.052 -70.76 -68.373 -0.109
Income Available to Common Incl. Extra. Items -101.052 -70.76 -68.373 -0.109
Diluted Net Income -101.052 -70.76 -68.373 -0.109
Diluted Weighted Average Shares 54.8737 28.9193 58.079 58.079
Diluted EPS Excluding Extraordinary Items -1.84154 -2.44681 -1.17724 -0.00188
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.84154 -2.44681 -1.17724 -0.00188
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 58.159 26.45 26.751 26.154 26.776
Selling/General/Admin. Expenses, Total 7.455 7.623 8.289 7.852 8.999
Research & Development 13.508 16.244 18.462 18.302 17.777
Operating Income -58.159 -26.45 -26.751 -26.154 -26.776
Interest Income (Expense), Net Non-Operating
Other, Net 2.845 2.587 2.152 1.472 0.84
Net Income Before Taxes -55.314 -23.934 -24.599 -24.682 -25.936
Net Income After Taxes -55.314 -23.934 -24.599 -24.682 -25.936
Net Income Before Extra. Items -55.314 -23.934 -24.599 -24.682 -25.936
Net Income -55.314 -23.934 -24.599 -24.682 -25.936
Income Available to Common Excl. Extra. Items -55.314 -23.934 -24.599 -24.682 -25.936
Income Available to Common Incl. Extra. Items -55.314 -23.934 -24.599 -24.682 -25.936
Diluted Net Income -55.314 -23.934 -24.599 -24.682 -25.936
Diluted Weighted Average Shares 56.7453 55.8645 55.7199 55.2061 54.5729
Diluted EPS Excluding Extraordinary Items -0.97478 -0.42843 -0.44148 -0.44709 -0.47525
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.31929 -0.38092 -0.44148 -0.44709 -0.47525
Unusual Expense (Income) 37.196 2.583
Gain (Loss) on Sale of Assets 0 -0.071
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 275.365 381.736 21.103 0.006
Cash and Short Term Investments 268.229 376.976 19.782 0.006
Cash & Equivalents 47.73 376.976 19.782 0.006
Prepaid Expenses 7.136 4.76 1.286 0
Other Current Assets, Total 0 0.035 0
Total Assets 321.902 401.987 22.564 0.006
Property/Plant/Equipment, Total - Net 28.21 18.081 1.461 0
Total Current Liabilities 13.043 12.143 32.048 2.224
Accounts Payable 2.608 2.453 0.63 0
Accrued Expenses 10.435 9.69 2.356 0.019
Notes Payable/Short Term Debt 0 0 0 2.205
Other Current Liabilities, Total 0 29.062 0
Total Liabilities 25.611 17.937 32.364 2.224
Total Long Term Debt 0 0 0 0
Other Liabilities, Total 12.568 5.794 0.316 0
Total Equity 296.291 384.05 -9.8 -2.218
Redeemable Preferred Stock 0 0 55.608 0
Common Stock 0.001 0.001 0 0
Additional Paid-In Capital 539.741 525.4 5.183 0
Retained Earnings (Accumulated Deficit) -242.403 -141.351 -70.591 -2.218
Total Liabilities & Shareholders’ Equity 321.902 401.987 22.564 0.006
Total Common Shares Outstanding 58.2218 58.0108 58.079 58.079
Property/Plant/Equipment, Total - Gross 31.417 18.936 1.582
Accumulated Depreciation, Total -3.207 -0.855 -0.121
Other Long Term Assets, Total 3.005 2.17
Short Term Investments 220.499
Long Term Investments 15.322
Other Equity, Total -1.048
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 238.783 251.171 270.307 275.365 298.492
Cash and Short Term Investments 233.986 246.665 264.096 268.229 291.685
Cash & Equivalents 182.988 128.506 69.811 47.73 56.391
Prepaid Expenses 4.777 2.878 6.211 7.136 6.807
Other Current Assets, Total 0.02 1.628
Total Assets 266.228 287.044 309.996 321.902 334.845
Property/Plant/Equipment, Total - Net 25.729 33.802 37.084 28.21 20.39
Property/Plant/Equipment, Total - Gross 26.567 37.077 40.946 31.417 22.915
Accumulated Depreciation, Total -0.838 -3.275 -3.862 -3.207 -2.525
Other Long Term Assets, Total 1.716 2.071 2.605 3.005 2.56
Total Current Liabilities 12.537 12.27 14.341 13.043 13.524
Accounts Payable 3.753 2.72 1.992 2.608 3.972
Accrued Expenses 8.784 9.55 12.349 10.435 9.552
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total
Total Liabilities 62.209 62.898 33.772 25.611 18.392
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 49.672 50.628 19.431 12.568 4.868
Total Equity 204.019 224.146 276.224 296.291 316.453
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 548.249 546.067 543.029 539.741 535.852
Retained Earnings (Accumulated Deficit) -344.136 -321.651 -266.337 -242.403 -217.804
Total Liabilities & Shareholders’ Equity 266.228 287.044 309.996 321.902 334.845
Total Common Shares Outstanding 57.9719 57.9893 58.1948 58.2218 58.1493
Short Term Investments 50.998 118.159 194.285 220.499 235.294
Long Term Investments 0 0 0 15.322 13.403
Other Equity, Total -0.095 -0.271 -0.469 -1.048 -1.596
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -101.052 -70.76 -68.373 -0.109
Cash From Operating Activities -87.98 -52.852 -8.721 -0.019
Cash From Operating Activities 2.352 0.734 0.121 0
Non-Cash Items 17.928 19.672 57.822 0.08
Changes in Working Capital -7.208 -2.498 1.709 0.01
Cash From Investing Activities -241.863 -5.74 -1.545 0
Capital Expenditures -6.594 -5.74 -1.545 0
Cash From Financing Activities 0.597 417.467 30.077 0
Issuance (Retirement) of Stock, Net 0.676 417.467 25.077 0
Issuance (Retirement) of Debt, Net 0 5 0
Net Change in Cash -329.246 358.875 19.811 -0.019
Other Investing Cash Flow Items, Total -235.269
Financing Cash Flow Items -0.079
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -23.934 -101.052 -76.453 -51.771 -25.835
Cash From Operating Activities -21.074 -87.98 -65.551 -43.334 -21.24
Cash From Operating Activities 0.654 2.352 1.67 1.018 0.44
Non-Cash Items 3.267 17.928 13.887 9.723 4.839
Changes in Working Capital -1.061 -7.208 -4.655 -2.304 -0.684
Cash From Investing Activities 43.163 -241.863 -255.387 -258.883 -170.666
Capital Expenditures -0.383 -6.594 -5.573 -4.658 -3.273
Cash From Financing Activities -0.008 0.597 0.353 0.412 0
Financing Cash Flow Items -0.008 -0.079 -0.079 -0.015 0
Issuance (Retirement) of Stock, Net 0.676 0.432 0.427 0
Net Change in Cash 22.081 -329.246 -320.585 -301.805 -191.906
Issuance (Retirement) of Debt, Net
Other Investing Cash Flow Items, Total 43.546 -235.269 -249.814 -254.225 -167.393
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Versant Ventures Venture Capital 28.3133 16416117 0 2023-03-31 LOW
EcoR1 Capital, LLC Hedge Fund 14.7265 8538446 0 2023-06-30 LOW
Samsara BioCapital, LLC Venture Capital 14.59 8459314 0 2023-06-30 LOW
Porteus (Matthew) Individual Investor 6.0857 3528529 0 2023-03-31 LOW
Tang Capital Management, LLC Hedge Fund 3.5971 2085625 57159 2023-06-30 MED
Prosight Capital Hedge Fund 2.932 1700000 823334 2023-06-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.6468 1534623 1064173 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.3795 1379642 145204 2023-06-30 LOW
Citadel Advisors LLC Hedge Fund 2.0771 1204295 33118 2023-06-30 LOW
Lehrer-Graiwer (Joshua) Individual Investor 2.0036 1161670 0 2023-03-31 LOW
Stanford Management Company Endowment Fund 1.2126 703071 0 2023-06-30
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8937 518170 270790 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.7605 440967 351816 2023-06-30 LOW
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 0.7008 406308 0 2023-06-30 LOW
OUP Management Co., LLC Venture Capital 0.7008 406308 0 2023-06-30 LOW
Two Sigma Investments, LP Hedge Fund 0.5643 327204 -25292 2023-06-30 HIGH
Gutry (Phil) Individual Investor 0.5577 323355 24884 2023-03-31 LOW
Privium Fund Management (UK) Ltd Investment Advisor 0.4534 262858 -18903 2023-06-30 HIGH
Renaissance Technologies LLC Hedge Fund 0.421 244100 15900 2023-06-30 HIGH
Bellecapital Partners AG Investment Advisor/Hedge Fund 0.4104 237944 0 2023-02-28 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Graphite Bio, Inc. Company profile

About Graphite Bio Inc

Graphite Bio, Inc. is clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. The Company's gene editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. The Company's pipeline includes multiple programs including its gene replacement program, GPH201 for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene prevent normal immune system function, and targeted gene insertion program, GPH301 for Gaucher disease, and multiple additional programs in both HSCs and other cell types.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Graphite Bio Inc revenues was not reported. Net loss increased 3% to $70.8M. Higher net loss reflects Research and development - Balancing val increase from $9M to $35.2M (expense), General and administrative - Balancing v increase from $4.3M to $17.3M (expense), Stock-based Compensation in SGA increase from $54K to $5.2M (expense).

Industry: Bio Therapeutic Drugs

611 Gateway Blvd, Suite 120
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

ETH/USD

2,208.82 Price
+1.230% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 6.00

US100

15,946.40 Price
-0.260% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.63 Price
+0.320% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

EUR/USD

1.09 Price
+0.030% 1D Chg, %
Long position overnight fee -0.0080%
Short position overnight fee -0.0003%
Overnight fee time 22:00 (UTC)
Spread 0.00006

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading